Brief: Elanco Secures Approval Of Zenrelia(Ilunocitinib) In The European Union (EU)
24/07/2025 23:05
July 24 (Reuters) - Elanco Animal Health Inc ELAN.N: ELANCO SECURES APPROVAL OF ZENRELIA™ (ILUNOCITINIB) IN THE EUROPEAN UNION (EU), LAUNCHING INNOVATIVE CANINE DERMATOLOGY TREATMENT FOR ITCHY DOGS ELANCO ANIMAL HEALTH INC - ZENRELIA LAUNCH IMMEDIATELY IN MARKET BY Q3 2025 Source text: ID:nPn8PF3lSa Further company coverage: ELAN.N
Recent news on Elanco Animal Health Incorporated
See all newsBrief: Elanco Animal Health Appoints Jamie Preston As Chief People Officer
U.S. STOCKS ON THE MOVE-Walt Disney, Alphabet, Kraft Heinz
U.S. STOCKS ON THE MOVE-Wynn Resorts, Griffon, Kratos Defense, Amgen
Elanco Animal Health Incorporated reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVE-Cencora, Charles River, Twist Bioscience